Composition containing magnesium salt and Ackerman's bacteria and application

Abstract

The invention discloses a composition containing magnesium salt and Ackerman bacteria and application of the composition. The invention belongs to the technical field of dietary nutrition supplements. Wherein the composition further comprises a plant extract and a polysaccharide component, and can be used for relieving flatulence, stomachache, diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease and other intestinal tracts; the composition can increase the defecation amount, increase the defecation volume, soften excrement, shorten the defecation time, repair the intestinal tract, lubricate the intestinal tract, repair the intestinal tract barrier, increase beneficial bacteria and regulate the intestinal flora balance, and has the effects of immunity, inflammation resistance and metabolism promotion.

Description

[0001] This application claims priority to Chinese Application No. 202410646230.9, filed on May 23, 2024, entitled “A Composition Containing Magnesium Salt and Probiotics and Uses”, the contents of which are incorporated herein by reference in their entirety. Technical Field

[0002] The invention belongs to the field of dietary nutritional supplements and relates to a composition containing magnesium salt and Akkermansia. The composition further contains plant extracts and polysaccharides. The composition is used in relieving intestinal problems such as flatulence, abdominal pain, diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, etc. Background Art

[0003] Constipation is a condition characterized by a decrease in the number of bowel movements or difficulty in defecation, hard stools, or a feeling that the rectum is not completely emptied after defecation, which affects people's quality of life. Exercise, a high-fiber diet, and adequate fluid intake are the best ways to prevent constipation. In addition, taking some dietary nutritional supplements plays an effective role in relieving constipation.

[0004] Osmotic agents promote the entry of large amounts of water into the large intestine, softening and loosening the stool. Excessive fluid stretches the large intestine wall and stimulates contraction. Some salts, including those containing magnesium ions and phosphate ions, such as magnesium hydroxide, magnesium sulfate, and magnesium phosphate, stimulate intestinal movement by promoting osmosis, thereby having the effect of clearing the intestine and removing intestinal toxins.

[0005] In addition, intestinal flora is the core part of the intestinal microecology, and probiotics play a role in maintaining intestinal homeostasis and treating intestinal diseases. Intestinal probiotics adhere to the intestinal wall through adhesion, further colonize, and then form a microbial film on the surface of the adhesion film to prevent foreign bacteria from invading and protect the health of the intestinal mucosa.

[0006] Providing an effective dietary nutritional supplement, the composition of which can be used to relieve flatulence, abdominal pain, diarrhea, constipation, irritable bowel syndrome, and inflammatory bowel disease is a technical problem to be solved. Summary of the invention

[0007] The object of the present invention is to provide a composition containing magnesium salt and Akkermansia in view of the deficiencies of the prior art.

[0008] Furthermore, the magnesium salt is one or a combination of magnesium hydroxide, magnesium sulfate, magnesium phosphate, magnesium oxide, magnesium citrate, magnesium carbonate, magnesium chloride, magnesium threonate, and magnesium gluconate.

[0009] The content of the magnesium salt of the present invention is not less than 250 mg / portion; preferably, not less than 350 mg / portion; preferably, not less than 450 mg / portion.

[0010] The Akkermansia described in the present invention is Akkermansia muciniphila (Akk bacteria), and further comprises live Akk bacteria and / or Akk postbiotics.

[0011] Furthermore, the Akk bacteria content is not less than 1 billion per composition; preferably, not less than 3 billion per composition; more preferably, not less than 5 billion per composition.

[0012] The composition of the present invention also includes other types of postbiotics.

[0013] The postbiotics in the present invention may be in the form of a paste, a suspension, an emulsion, a powder, or a granule, preferably in the form of a powder.

[0014] The other types of postbiotics described in the present invention further include one or a combination of Lactobacillus casei, Lactobacillus plantarum, Bifidobacterium breve, Streptococcus thermophilus, Bifidobacterium bifidum, Lactobacillus rhamnosus, γ-aminobutyric acid, short-chain fatty acids, and tryptophan.

[0015] The postbiotic content of the present invention is not less than 1 billion per serving of the composition, preferably, not less than 5 billion per serving; preferably, not less than 10 billion per serving.

[0016] Furthermore, the composition also includes other probiotics.

[0017] Furthermore, the other probiotics are one or a combination of Lactobacillus, Lactobacillus dry, Bifidobacterium, Lactobacillus, Lactobacillus acidophilus, Bacillus licheniformis, Streptococcus faecalis, Bacillus subtilis, Bacillus butyricum, and Clostridium butyricum.

[0018] The amount of other probiotics described in the present invention is not less than 1 billion per composition, preferably, not less than 5 billion per composition; preferably, not less than 10 billion per composition.

[0019] The other probiotics and other types of postbiotics described in the present invention are present in an amount of no less than 1 billion per serving, preferably no less than 5 billion per serving; preferably no less than 10 billion per serving.

[0020] Furthermore, the composition comprises a polysaccharide.

[0021] The polysaccharide of the present invention is derived from extracts of okra, mallow, hollyhock, winter mallow, dandelion, scutellaria, chrysanthemum, Agaricus blazei, quinoa, jujube, apple, auricularia auricula, ginseng, purple sweet potato, bamboo fungus, enoki mushroom, wolfberry and Cordyceps militaris.

[0022] The content of the polysaccharide of the present invention is not less than 1 mg / portion; preferably, not less than 3 mg / portion; preferably, not less than 10 mg / portion.

[0023] Polysaccharides are widely present in the tissue cells of plants, animals and microorganisms. Polysaccharide extracts can lubricate the intestinal lining and repair intestinal epithelial cells; they can also regulate the richness of intestinal flora, increase the level of beneficial bacteria, and lower the pH value of the intestine.

[0024] Polysaccharide extracts can be obtained by water extraction, microwave extraction, enzymatic extraction, and ultrasonic extraction.

[0025] The composition of the present invention further comprises a plant extract.

[0026] The plant extract of the present invention comprises one or more of orange peel extract, fennel extract, clove extract and liquorice extract.

[0027] Furthermore, the plant extracts of the present invention are orange peel extract, fennel extract, clove extract, and licorice extract.

[0028] Furthermore, the total content of the polysaccharides and plant extracts of the present invention is not less than 1 mg / portion; preferably, not less than 1.5 mg / portion.

[0029] Furthermore, the composition of the present invention does not include stimulant laxatives, wherein the stimulant laxatives are one or a combination of fenofurtalline, bisacetylphenidate and anthraquinones.

[0030] The stimulant laxative of the present invention is one or a combination of aloe, senna leaf, rhubarb, bamboo leaf, senna leaf, cassia seed, castor oil and phenolphthalein.

[0031] Stimulant laxatives act on the enteric nervous system. Long-term use can easily lead to drug dependence, cause the intestines to blacken, and increase the risk of colon cancer.

[0032] The product of the composition described in the present invention can be in various dosage forms, including but not limited to common dosage forms of medicines, such as powders, suppositories, gels, oral liquids, liquid preparations, capsules, soft capsules, powders, granules, tablets, and crystal balls, and can also be common dosage forms of health foods and dietary supplements, such as tablets, hard capsules, soft capsules, beverages, solid beverages, soft drinks, soluble beans, freeze-dried powder, milk beans, chocolate, sandwich soft candies, sandwich chocolates, tea beverages, cold brew coffee, and soft candies.

[0033] The various dosage forms of the product for treating and / or improving intestinal health described in the present invention can be prepared according to conventional production and preparation methods of medicines, health foods, ordinary foods, daily chemicals, feeds, additives, etc. One or more carriers in the component are mixed and then prepared into the desired dosage form.

[0034] Probiotics are active microorganisms. Their proliferation is beneficial to inhibiting the proliferation of harmful bacteria, enhancing the intestinal mucosal barrier, reducing intestinal inflammation, inhibiting the activity of pathogenic bacteria, regulating cell proliferation and apoptosis responses, and other mechanisms to maintain the body's gastrointestinal health, improve intestinal flora, and form a healthy gastrointestinal ecosystem.

[0035] Postbiotics are inanimate microorganisms, and their main components are inactivated bacteria, bacterial lysates, cell wall components and metabolites. Beneficial metabolites of probiotics, such as r-aminobutyric acid, short-chain fatty acids, tryptophan, etc., are also components of postbiotics, which maintain the integrity of the intestinal barrier by regulating the intestinal flora.

[0036] The present invention provides a magnesium salt and Akkermansia composition, and use of the magnesium salt and Akkermansia composition in preparing a composition for relieving intestinal problems such as flatulence, abdominal pain, diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, etc.

[0037] The present invention provides a composition of okra, magnesium oxide and Akkermansia, wherein Akkermansia regulates the intestines and restores intestinal health. The composition does not contain irritant laxative ingredients. The composition effectively helps smooth and regular bowel movements, and is used in relieving intestinal problems such as constipation, flatulence, abdominal pain, diarrhea, etc.; the composition can increase the amount of bowel movements, increase the volume of bowel movements, soften the stool, reduce the time required for bowel movements, repair the intestines, lubricate the intestines, repair the intestinal barrier, increase beneficial bacteria, regulate the balance of intestinal flora, and has the effects of immunity, anti-inflammatory, and promoting metabolism.

[0038] The composition of the present invention can achieve the first bowel movement within 12 hours.

[0039] Furthermore, the composition of the present invention can achieve the first bowel movement within 8 hours.

[0040] Explanation of terms The "postbiotics" used in this article is a general term for the beneficial bacteria components after probiotics are processed, including bacteria and metabolites.

[0041] The "polysaccharide" used in this article is composed of multiple monosaccharide molecules connected by glycosidic bonds. It is a type of carbohydrate substance with a complex and bulky molecular structure.

[0042] The "extract" used in this article refers to the product obtained by directing and concentrating the raw materials through the process of physical and chemical extraction and separation. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 This is a statistical diagram of the defecation efficiency after taking the composition of the present invention. Figure 2 This is a statistical diagram of effective body sensation of defecation after taking the composition of the present invention DETAILED DESCRIPTION

[0044] In order to facilitate the understanding of those skilled in the art, the present invention is further described below in conjunction with embodiments, and the contents mentioned in the implementation modes are not intended to limit the present invention. Example

[0045] A composition comprises magnesium oxide and Lactobacillus casei, wherein the content of magnesium is 350 mg / portion, and the Lactobacillus casei is an inactivated bacterium with a bacterial cell volume of 1 billion cells / portion. Example

[0046] A composition comprises magnesium hydroxide and Lactobacillus plantarum, wherein the magnesium content is 350 mg, and the Lactobacillus plantarum is an inactivated bacterium with a bacterial cell volume of 1 billion cells / portion. Example

[0047] A composition comprises magnesium sulfate and salivary lactobacillus, wherein the magnesium content is 350 mg and the salivary lactobacillus has a bacterial cell volume of 1 billion CFU / portion. Example

[0048] A composition comprises magnesium phosphate and Lactobacillus acidophilus, wherein the magnesium content is 350 mg and the Lactobacillus acidophilus bacterial cell quantity is 1 billion CFU / portion. Example

[0049] A composition comprises magnesium citrate and Bifidobacterium breve, wherein the magnesium is 350 mg and the bacterial cell quantity of Bifidobacterium breve is 1 billion CFU / portion. Example

[0050] A composition comprises magnesium carbonate and thermophilic streptococcus, wherein the magnesium content is 350 mg and the thermophilic streptococcus has a bacterial cell volume of 1 billion CFU / portion. Example

[0051] A composition comprises magnesium chloride and Lactobacillus casei, wherein the magnesium content is 250 mg, and the Lactobacillus casei is an inactivated bacterium with a cell volume of 5 billion cells / portion. Example

[0052] A composition comprises magnesium threonate and Lactobacillus rhamnosus, wherein the magnesium content is 350 mg and the Lactobacillus rhamnosus bacterial cell quantity is 1 billion CFU / portion. Example

[0053] A composition comprises magnesium gluconate and Bifidobacterium bifidum, wherein the magnesium content is 350 mg and the cell quantity of Bifidobacterium bifidum is 1 billion CFU / portion. Example

[0054] A composition comprises magnesium oxide and lactobacillus, wherein the magnesium content is 250 mg and the lactobacillus cell count is 5 billion CFU / portion. Example

[0055] A composition comprises magnesium oxide and bifidobacteria, wherein the magnesium content is 250 mg and the bifidobacteria content is 5 billion CFU / portion. Example

[0056] A composition comprises magnesium oxide and Clostridium butyricum, wherein the magnesium content is 250 mg and the Clostridium butyricum bacterial volume is 5 billion CFU / portion. Example

[0057] A composition comprises magnesium oxide and Akkermansia, wherein the amount of magnesium is 250 mg and the amount of Akkermansia is 5 billion CFU / portion. Example

[0058] A composition comprises magnesium oxide, Lactobacillus casei and okra extract, wherein the magnesium content is 250 mg and the Lactobacillus casei bacterial cell quantity is 5 billion cells / portion. Example

[0059] A composition comprises magnesium oxide, Lactobacillus casei, okra extract and licorice extract, wherein the magnesium content is 350 mg and the Lactobacillus casei bacterial cell quantity is 5 billion cells / portion. Example

[0060] A composition comprises magnesium oxide, Lactobacillus casei, pasteurized Akkermansia muciniphila (Akk pasteurized bacteria), okra extract, licorice extract, orange peel extract, fennel extract, and clove extract, wherein the magnesium content is 250 mg, and the Akk pasteurized bacteria content is 5 billion cells / portion. Example

[0061] A composition comprises magnesium oxide, pasteurized Akkermansia muciniphila (Akk pasteurized bacteria), okra extract, licorice extract, orange peel extract, fennel extract and clove extract, wherein the magnesium content is 350 mg and the Akk pasteurized bacteria content is 5 billion cells / portion. Example

[0062] A preparation method of a composition, the composition comprising magnesium oxide and Lactobacillus casei, wherein the magnesium content is 450 mg, the Lactobacillus casei is an inactivated bacterium, and the bacterial volume is 5 billion cells / portion. The magnesium oxide, Lactobacillus casei and auxiliary materials are crushed, sieved, further mixed, tableted, and coated. Example

[0063] A method for preparing a composition, the composition comprising magnesium oxide and Akkermansia, wherein the magnesium content is 450 mg and the Akkermansia cell mass is 5 billion cells / portion. The magnesium oxide, Akkermansia and auxiliary materials are crushed, sieved and further mixed to obtain a uniformly mixed pre-capsule filling material, which is then filled into capsule shells to obtain capsules. Example

[0064] A preparation method of a composition, the composition comprising magnesium oxide, pasteurized Akkermansia muciniphila (Akk pasteurized bacteria), okra extract, licorice extract, orange peel extract, fennel extract, and clove extract. The composition and auxiliary materials are crushed and sieved respectively, further mixed, tableted, and coated. Example

[0065] A preparation method of a composition, the composition comprising magnesium oxide, lactobacillus casei, pasteurized Akkermansia muciniphila (Akk pasteurized bacteria), okra extract, licorice extract, orange peel extract, fennel extract, and clove extract. Magnesium oxide, lactobacillus casei, pasteurized Akk, okra extract, licorice extract, orange peel extract, fennel extract, and clove extract are uniformly mixed, a plant material protective layer is sprayed on the outer core of the mixture to form a buffer layer coating for wrapping and protection, and finally the mixture is mixed with auxiliary materials to form a gel-like substance, which is then formed into crystal balls by a pelletizing machine. Example

[0066] Mouse experiment, experimental method: mice were given loperamide 8 mg / (kg·d) to induce constipation in mice; 0.5 h after the last administration, the mice were given oral gavage treatment according to the above example, with an oral gavage dose of 250 mg / (kg·d), and the first defecation time of the mice, 24h feces weight and feces water content were recorded.

[0067] Time to first defecation: the time from the end of gavage to the first defecation; Total weight of feces: the total weight of feces excreted by each mouse within 24 hours after gavage (calculated as the average value of mice in the group) Fecal moisture content% = (fecal wet weight - fecal dry weight) / fecal wet weight * 100% The results are shown in the following table: Table 1 Animal experiment on the effect of the composition on relieving constipation Grouping Time to first bowel movement (min) Stool weight (g) Water content of stool (%) Constipation group 427.5±89.19 0.92±0.28 21.73±6.19 Example 1 179.88±67.28 1.78±0.63 50.18±5.11 Example 2 186.82±66.29 1.94±0.55 49.19±6.27 Example 3 182.74±68.91 1.91±0.51 51.92±5.83 Example 4 186.98±70.19 1.83±0.51 52.90±5.18 Example 5 185.17±65.28 1.87±0.62 48.12±4.75 Example 6 187.91±64.37 2.20±0.68 57.81±6.12 Example 7 191.99±67.28 1.99±0.67 55.27±5.16 Example 8 181.81±65.29 1.91±0.56 52.91±5.73 Example 9 177.29±67.21 2.07±0.55 51.82±5.82 Example 10 288.67±70.19 2.28±0.68 59.98±5.19 Embodiment 11 290.98±68.18 2.37±0.69 57.19±5.92 Example 12 289.83±78.28 2.22±0.71 57.21±5.76 Example 13 283.28±71.92 2.31±0.68 59.43±5.29 Embodiment 14 278.63±77.71 2.09±0.57 60.19±5.17 Embodiment 15 191.27±59.18 2.19±0.58 60.25±5.23 Example 16 149.88±58.17 2.65±0.72 70.21±6.16 Embodiment 17 148.96±68.14 2.71±0.66 70.34±6.23 Embodiment 18 156.19±60.18 2.51±0.67 67.77±6.17 Embodiment 19 149.87±59.09 2.67±0.68 69.65±6.5 Embodiment 20 148.61±56.18 2.74±0.73 71.12±5.19 Embodiment 21 147.46±58.44 2.83±0.52 72.11±5.27 As can be seen from Table 1, after taking the magnesium salt and probiotic composition, the defecation time is significantly improved, and the amount of feces is increased to a certain extent, making the feces softer, and the water content of the feces of constipated mice can be normalized. Example

[0068] In the human test, 172 people who had constipation were recruited (including 166 females and 6 males, and there was no stubborn and incurable population, and individual differences did not affect the statistics). The volunteers took tablets containing the composition of the present invention (such as Example 20) every day, and the changes in their bowel habits were observed.

[0069] Efficacy evaluation: Markedly effective: The constipation symptoms of the patients were significantly improved, the interval between bowel movements was shortened, or the dry stool was improved, or the bowel movements were smoother, or the frequency of bowel movements increased, or the time spent in the toilet was reduced, and other symptoms were significantly improved; Ineffective: The patient's constipation symptoms did not change.

[0070] Effective rate = significant effect / total number of samples; The experimental results are as follows Figure 1 , Figure 2 shown.

[0071] As can be seen from the figure, after the volunteers ingested the composition prepared by the present invention, they all showed good therapeutic effects, and were able to ensure defecation within 8 hours and defecation within 12 hours. At the same time, other symptoms were significantly improved, including increased defecation volume, increased defecation volume, reduced toilet time, softened stool, lubricated intestines, etc.

[0072] It will be understood by those skilled in the art that, unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as generally understood by those skilled in the art in the art to which the present invention belongs. It should also be understood that terms such as those defined in general dictionaries should be understood to have meanings consistent with the meanings in the context of the prior art, and will not be interpreted with idealized or overly formal meanings unless specifically defined as herein.

[0073] It should be understood that the detailed description of the technical solutions of the present invention by means of the preferred embodiments is illustrative rather than restrictive. A person skilled in the art may modify the technical solutions described in the embodiments, or replace some of the technical features by equivalents, based on reading the specification of the present invention; and these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A composition, characterized in that Contains magnesium salts and Akkermansia.

2. The composition according to claim 1, characterized in that The Akkermansia is Akkermansia muciniphila (Akk bacteria), and further comprises live Akk bacteria and / or Akk postbiotics.

3. The composition according to claim 2, characterized in that The Akk postbiotics include inactivated bacteria, lysed bacteria and / or culture fluid containing dead Akk bacteria of Akk; further, the Akk postbiotics are inactivated bacteria of Akk; further, the inactivated bacteria of Akk are pasteurized Akk bacteria.

4. The composition according to claim 1, characterized in that The magnesium salt is one or a combination of magnesium hydroxide, magnesium sulfate, magnesium phosphate, magnesium oxide, magnesium citrate, magnesium carbonate, magnesium chloride, magnesium threonate, and magnesium gluconate.

5. The composition according to claim 4, wherein the content of magnesium in the magnesium salt is not less than 250 mg / portion.

6. The composition according to claim 1, characterized in that Other types of postbiotics are also included. Further, the other types of postbiotics include one or a combination of Lactobacillus casei, Lactobacillus plantarum, Bifidobacterium breve, Streptococcus thermophilus, Bifidobacterium bifidum, Lactobacillus rhamnosus, r-aminobutyric acid, short-chain fatty acids, and tryptophan.

7. The composition according to claim 2, characterized in that The Akk bacteria content is not less than 1 billion per composition.

8. The composition according to claim 6, characterized in that The content of other types of postbiotics is not less than 1 billion per serving of the composition.

9. The composition according to claim 1, characterized in that Other probiotics are also included; further, the other probiotics are one or a combination of Lactobacillus, Lactobacillus dry, Bifidobacterium, Lactobacillus, Lactobacillus acidophilus, Bacillus licheniformis, Streptococcus faecalis, Bacillus subtilis, Bacillus butyricum, and Clostridium butyricum.

10. The composition according to claim 9, characterized in that The amount of other probiotics is not less than 1 billion per composition.

11. The composition according to claim 1, characterized in that The composition also includes a polysaccharide.

12. The composition according to claim 11, wherein the polysaccharide is derived from extracts of okra, mallow, hollyhock, mallow, dandelion, scutellaria, chrysanthemum, Agaricus blazei, quinoa, jujube, apple, wood ear, ginseng, purple sweet potato, bamboo fungus, Flammulina velutipes, wolfberry, and Cordyceps militaris.

13. The composition according to claim 11, wherein the content of the polysaccharide is 0.001 to 0.1 g / portion.

14. The composition according to claim 1, characterized in that Further included are plant extracts.

15. The composition according to claim 14, wherein the plant extract is one or more of orange peel extract, fennel extract, clove extract, and liquorice extract.

16. The composition of claim 1 excluding a stimulant laxative.

17. The composition according to claim 16, wherein the stimulant laxative is one or a combination of fenofurtalline, bisacetylphenidate and anthraquinones.

18. The pharmaceutical composition according to claim 16, wherein the stimulant laxative is one or a combination of aloe, senna, rhubarb, bamboo leaf, senna leaf, cassia seed, castor oil, and phenolphthalein.

19. Use of the composition according to any one of claims 1 to 18 in relieving intestinal problems such as flatulence, abdominal pain, diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, etc.

20. The composition according to any one of claims 1 to 18, which is prepared into soft capsules, liquid preparations, granules, powders, capsules, tablets, or crystal spheres.

Images